Arcadia Investment Management Corp MI Acquires 1,615 Shares of DexCom, Inc. (NASDAQ:DXCM)

Arcadia Investment Management Corp MI boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 8,075.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 1,635 shares of the medical device company’s stock after acquiring an additional 1,615 shares during the period. Arcadia Investment Management Corp MI’s holdings in DexCom were worth $185,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Crewe Advisors LLC bought a new position in shares of DexCom during the first quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom during the second quarter worth approximately $25,000. DSM Capital Partners LLC bought a new position in DexCom during the 4th quarter worth $28,000. Riverview Trust Co acquired a new position in DexCom in the 1st quarter valued at $32,000. Finally, Smithfield Trust Co raised its holdings in DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The disclosure for this sale can be found here. Insiders sold a total of 3,483 shares of company stock valued at $369,052 in the last three months. Insiders own 0.30% of the company’s stock.

DexCom Trading Down 2.4 %

Shares of DexCom stock traded down $1.66 on Friday, hitting $67.39. The stock had a trading volume of 588,060 shares, compared to its average volume of 3,774,768. The stock has a 50 day moving average of $87.55 and a 200 day moving average of $113.28. The firm has a market capitalization of $26.80 billion, a P/E ratio of 44.55, a PEG ratio of 2.15 and a beta of 1.16. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue was up 15.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.34 EPS. Sell-side analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on DXCM. Morgan Stanley decreased their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Stifel Nicolaus raised their target price on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Redburn Atlantic started coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. Royal Bank of Canada reduced their price target on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Finally, Oppenheimer lowered their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.